Company Overview - Fractyl Health, Inc. is a metabolic therapeutics company focused on innovative approaches to treat obesity and type 2 diabetes (T2D) [3] - The company aims to shift the treatment of metabolic diseases from chronic symptomatic management to durable disease-modifying therapies targeting organ-level root causes [3] - Fractyl has a strong intellectual property portfolio with 32 granted U.S. patents and approximately 40 pending U.S. applications, along with numerous foreign patents [3] Upcoming Events - The company will report its financial results for the second quarter of 2025 and provide business updates on August 12, 2025, at 4:30 p.m. ET [1] - Harith Rajagopalan, M.D., Ph.D., Co-Founder and CEO, will present at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 11:30 a.m. ET [2] - A live webcast of the conference call and presentation will be available on Fractyl Health's website, with an archived version for later access [2]

Core Insights - Fractyl Health, Inc. has strengthened its intellectual property portfolio with the issuance of two new U.S. patents, enhancing its leadership in metabolic innovation and duodenal resurfacing technologies [1][2][3] Intellectual Property Developments - The company has built a robust patent portfolio since 2011, now comprising 31 granted U.S. patents and approximately 40 pending U.S. applications, along with numerous foreign patents [2][5] - The newly issued patents focus on electrical energy ablation systems for treating tissue, specifically targeting duodenal mucosa with thermal and non-thermal energy applications [3][4] Product and Clinical Development - Fractyl's lead product candidate, Revita, aims to remodel the duodenal lining to reverse damage caused by high-fat and high-sugar diets, which are root causes of metabolic diseases [6][7] - Revita has received U.S. FDA Breakthrough Device designation for weight maintenance in patients who discontinue GLP-1-based drugs [6][7] - The company is preparing for three key data readouts from its pivotal study of Revita, with significant milestones expected in June 2025, Q3 2025, and the second half of 2026 [4][5]